These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18175263)

  • 1. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
    Cheng Y; Paz K
    IDrugs; 2008 Jan; 11(1):46-56. PubMed ID: 18175263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
    DeAngelo DJ; Stone RM; Heaney ML; Nimer SD; Paquette RL; Klisovic RB; Caligiuri MA; Cooper MR; Lecerf JM; Karol MD; Sheng S; Holford N; Curtin PT; Druker BJ; Heinrich MC
    Blood; 2006 Dec; 108(12):3674-81. PubMed ID: 16902153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can FLT3 inhibitors overcome resistance in AML?
    Tam WF; Gary Gilliland D
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Wiernik PH
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
    Schittenhelm MM; Kampa KM; Yee KW; Heinrich MC
    Cell Cycle; 2009 Aug; 8(16):2621-30. PubMed ID: 19625780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 inhibitors in acute myeloid leukemia.
    el-Shami K; Stone RM; Smith BD
    Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
    Shabbir M; Stuart R
    Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
    Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
    J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells.
    Grafone T; Palmisano M; Nicci C; Martelli AM; Emanuela O; Storti S; Baccarani M; Martinelli G
    Hematol Oncol; 2008 Sep; 26(3):159-66. PubMed ID: 18383555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational drugs targeting FLT3 for leukemia.
    Ustun C; DeRemer DL; Jillella AP; Bhalla KN
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
    Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
    Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 inhibition in acute myeloid leukaemia.
    Knapper S
    Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
    Sritana N; Auewarakul CU
    Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
    Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
    Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lestaurtinib: a multi-targeted FLT3 inhibitor.
    Fathi AT; Levis M
    Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.
    Li WW; Wang XY; Zheng RL; Yan HX; Cao ZX; Zhong L; Wang ZR; Ji P; Yang LL; Wang LJ; Xu Y; Liu JJ; Yang J; Zhang CH; Ma S; Feng S; Sun QZ; Wei YQ; Yang SY
    J Med Chem; 2012 Apr; 55(8):3852-66. PubMed ID: 22452518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
    Stone RM; De Angelo J; Galinsky I; Estey E; Klimek V; Grandin W; Lebwohl D; Yap A; Cohen P; Fox E; Neuberg D; Clark J; Gilliland DG; Griffin JD
    Ann Hematol; 2004; 83 Suppl 1():S89-90. PubMed ID: 15124689
    [No Abstract]   [Full Text] [Related]  

  • 19. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
    Safaian NN; Czibere A; Bruns I; Fenk R; Reinecke P; Dienst A; Haas R; Kobbe G
    Leuk Res; 2009 Feb; 33(2):348-50. PubMed ID: 18573526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.